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Abstract
In cystic ﬁbrosis (CF), the airway surface liquid (ASL) is depleted. We previ-
ously demonstrated that lipoxin A4 (LXA4) can modulate ASL height (ASLh)
through actions on Cl transport. Here, we report novel effects of lipoxin on
the epithelial Na+ channel ENaC in this response. ASL dynamics and ion
transport were studied using live-cell confocal microscopy and short-circuit
current measurements in CF (CuFi-1) and non-CF (NuLi-1) cell cultures.
Low physiological concentrations of LXA4 in the picomolar range produced
an increase in ASLh which was dependent on inhibition of an amiloride-sensi-
tive Na+ current and stimulation of a bumetanide-sensitive Cl current. These
ion transport and ASLh responses to LXA4 were blocked by Boc-2 an inhibi-
tor of the speciﬁc LXA4 receptor ALX/FPR2. LXA4 affected the subcellular
localization of its receptor and enhanced the localization of ALX/FPR2 at the
apical membrane of CF cells. Our results provide evidence for a novel effect
of low physiological concentrations of LXA4 to inhibit airway epithelial Na
+
absorption that results in an ASL height increase in CF airway epithelia.
Introduction
The surface of the bronchi is covered by an airway surface
liquid (ASL) layer which is maintained at optimum height
by NaCl transport across the epithelium. Sodium absorp-
tion through the epithelial Na+ channel (ENaC) induces
water absorption and dehydrates the ASL, whereas
secretion of Cl via the cystic ﬁbrosis transmembrane
ª 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
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conductance regulator (CFTR) and Ca2+-activated Cl
channels have the opposite effect to hydrate the ASL
(Boucher 2004b; Blouquit-Laye and Chinet 2007).
Cystic ﬁbrosis (CF) is a lethal genetic disorder resulting
from a mutation of the CFTR gene (Riordan et al. 1989).
CFTR functions as a Cl channel and as a regulator of
other ion channels. In CF, the absence of CFTR inhibition
of ENaC results in increased isotonic absorption of Na+
and dehydration of the ASL layer (Stutts et al. 1995; Kun-
zelmann et al. 1997). ASL dehydration results in chronic
bacterial infection, persistent inﬂammation and progres-
sive lung destruction. The greatest therapeutic challenge
in CF is to restore ion transport function, enhance ASL
dynamics, and reduce infection (Tarran et al. 2001; Pisi
and Chetta 2009).
The endogenous lipoxin A4 is an eicosanoid that
triggers resolution of inﬂammation in a wide variety of
tissues. Lipoxins have been proposed as novel regulators
of immunity and may have therapeutic potential in
chronic immune disorders (Serhan et al. 1984a). LXA4
was shown to decrease pro-inﬂammatory cytokine IL-8
release, arrest neutrophilic inﬂammation, and decrease
infection in a mouse model of chronic airway inﬂamma-
tion and infection (Karp et al. 2004). CF has been associ-
ated with a reduced LXA4 level in bronchoalveolar lavage
(Karp et al. 2004; Starosta et al. 2006).
We have previously shown that high concentrations of
LXA4 (100 nmol/L) stimulated airway epithelium tight
junction formation (Grumbach et al. 2009), produced an
intracellular Ca2+ mobilization and Cl secretion (Bonn-
ans et al. 2003), and enhanced ASL height in bronchial
epithelial cells derived from patients with CF (Verriere
et al. 2012). Here, we report a role for low physiological
concentrations of LXA4 (1 nmol/L) in correcting Na
+ and
Cl transport and ASL height in a human cell model of
CF airway epithelium. These studies suggest a therapeutic
role for lipoxins as novel regulators for the correction of
Na+ and Cl transport dysfunction in CF airway.
Methods
Cell culture and Ussing chamber
experiments
NuLi-1 and CuFi-1 cell lines donated by Prof Zabner
(University of Iowa, USA) have typical bronchial epithe-
lial phenotype of mucus secretion and air–surface liquid
generation. The NuLi-1 cell line was derived from human
airway epithelium of normal genotype, whereas the CuFi-
1 line was derived from a CF patient with D508/D508
genotype (Zabner et al. 2003). NuLi-1 and CuFi-1 epithe-
lia were grown to well-differentiated monolayers under an
air–liquid interface (ALI). Cells were initially grown to
conﬂuency in ﬂasks using bronchial epithelial growth
medium (BEBM; Lonza, Bethesda, MD) with epidermal
growth factor, hydrocortisone, bovine pituitary extract,
transferring, bovine insulin, tri-iodothyronine, epineph-
rine, retinoic acid, penicillin-streptomycin (0.025 lg/mL),
gentamicin (0.05 ng/mL), and amphotericin (25 lg/mL).
When cell conﬂuence was conﬁrmed under visual
inspection, the medium was switched to DMEM/F-12
(Invitrogen, Auckland, New Zealand) to aid cell differen-
tiation. This medium was supplemented with Ultroser G
(2%, Pall Biospera, Cergy-Saint-Christophe, France),
which enhances ion transport (Zabner et al. 2003), and
penicillin-streptomycin (0.025 lg/mL), gentamicin
(0.05 ng/mL), and amphotericin (25 lg/mL). The culture
medium at the apical aspect was aspirated every 3–4 days
until the establishment of an air–liquid interface. The ba-
solateral culture medium was replaced every 2–3 days.
After 4–6 weeks, the cells formed a polarized conﬂuent
monolayer, differentiated clear cells, and mucin-secreting
cells, beating cilia and a high transepithelial electrical
resistance (TER) of >700 O/cm2.
Airway surface liquid height measurements
The ASL height in Nuli-1 and CuFi-1 epithelia was mea-
sured by confocal ﬂuorescence microscopy using a protocol
adapted from (Tarran and Boucher 2002). To label the
ASL, 8 lL PBS containing 1 mg/mL Texas red-dextran
(10 kD; Invitrogen) was added to the apical ﬂuid overlying
the well-differentiated airway epithelium. The epithelial
cells were stained using calcein green-AM (5 μmol/L, Invi-
trogen) dissolved in medium culture for 30 min and intro-
duced to the basolateral compartment of the insert. The
FluorinetTM electronic ﬂuid Perﬂuorocarbon 72 (FC-72;
3M, St Paul, MN) was added to the apical compartment of
the insert at a volume of 0.5 mL. Perﬂuorocarbon 72 is
immiscible with the ASL and was used to prevent ASL
evaporation on transferring the inserts from the incubator
to the microscope stage and during the confocal scanning
experiments. Fluorescent images of the epithelial layer and
ASL height were obtained using a confocal microscope
(Zeiss LSM 510 Meta 409 objective, Jena, Germany). The
average ASL height was recorded within the microscope
ﬁeld from a XZ scan of a 9-point square matrix yielding
eight separate ASL height measurement vectors. Images
were analyzed using the Zeiss LSM Image analyzer software
(Carl Zeiss Microlmaging GmbH, Jena, Germany).
Immunocytochemistry
NuLi-1 and CuFi-1 cells were grown in air–liquid inter-
face until differentiation at 4–6 weeks and ﬁnally ﬁxed in
4% (w/v) paraformaldehyde in PBS for 30 min on ice.
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After two washes in PBS, cells were then permeabilized in
0.4% (v/v) Triton-X-TBS for 5 min, and then blocked in
3% (w/v) BSA in PBS. Cells were incubated for 2 h on
ice with the primary antibody,
To visualize the LXA4 receptor, a rabbit polyclonal
anti-FPRL-1 antibody was diluted 1:600 in PBS. After
three washes in PBS, cells were incubated for 1 h on ice
with the secondary antibody; AlexaFluor 488-conjugated
anti-Rabbit (Invitrogen) diluted 1:400 in 2% (w/v) PBS.
Cells were washed three times in PBS and ﬁnally mounted
in Vectashield mounting solution (Vector Laboratories,
Burlingame, CA) containing DAPI blue.
The subcellular distribution of FPR2/ALXR was
observed using a LSM 710 confocal microscope (Zeiss,
Welwyn Garden City, UK), equipped with an Argon laser
and a HeNe laser. The Alexaﬂuor 488-labeled anti-rabbit
antibody was visualized using a 488 nm excitation
wavelength and 505–530 nm emission range. DAPI was
visualized using a 364 nm excitation wavelength and 385–
470 nm detection range. Rhodamine-phalloidin was used
to stain f-actin ﬁlaments in the cellular cytoskeleton and
was visualized using a 543 nm excitation wavelength and
560–630 nm detection range. To stain the plasma mem-
brane, Wheat germ agglutinin (WGA) was used to visual-
ize using a 568 nm excitation wavelength to highlight the
plasma membrane.
Short-circuit current (ISC) recordings
Differentiated NuLi-1 and CuFi-1 epithelial monolayers
were mounted in Ussing chambers (Physiological
Instruments, San Diego, CA). The bathing Krebs solution
was composed of 140 mmol/L NaCl, 5.2 mmol/L KCl,
0.8 mmol/L MgCl2, 1.2 mmol/L CaCl2, 0.4 mmol/L
KH2PO4, 2.4 mmol/L K2HPO4, 25 mmol/L NaHCO3,
10 mmol/L HEPES (free acid), and 10 mmol/L Glucose.
Chambers were constantly gassed with a mixture of 95%
O2/5%CO2 at 37°C, which maintained the pH at 7.4 and
established a circulating perfusion within the Ussing
chamber. The spontaneous transmembrane potential was
measured and clamped to 0 mV by application of a short-
circuit current using a voltage clamp model ampliﬁer (EVC
4000, World Precision Instrument, Sarasota, FL).
Flow cytometry
Cells, 5 9 105, from ALI cultures were isolated and resus-
pended in 100 μL of FACS buffer (0.2% FCS, 0.02%
sodium azide in PBS). A directly labeled IgG anti-ALX/
FPR2 antibody was added according to the manufacturers
recommendations, followed by an IgG2b isotype control
and incubated for 30 min on ice. Cells were then washed
three times in cold PBS before suspension in 300 lL
FACS buffer. The samples were analyzed on an Epics
XL-MCL ﬂow cytometer in triplicates (Beckman Coulter
AB45298 using Expo 32 analysis (Applied cytometry
systems, Shefﬁeld, U.K.).
Drugs
Lipoxin A4 was obtained from Calbiochem (Merck KGaA,
Darmstad, Germany) and aliquots (104 mol/L in etha-
nol) were stored at 80°C. Where indicated, cells were
preincubated with the peptide Boc-Phe-Leu-Phe-Leu-Phe
(Boc-2) (Phoenix pharmaceutical, Burlingame, CA) at
105 mol/L for 60 min at 37°C before treatment with
LXA4. Bumetanide (Sigma, St Louis, MO) was stored at
0.1 mol/L in DMSO and used at ﬁnal concentration of
10 lmol/L. Amiloride (1 lmol/L; Sigma) applied on the
apical side was dissolved in FC-72.
Statistical analysis
All the experiments were performed at least on three sep-
arate occasions (n ≥ 3). Results are given as mean
value  standard error of the mean obtained from n
independent experiments. Student’s t-test was used to
compare two populations. Analysis of variance (ANOVA)
was performed for multiple comparisons, P < 0.05
was treated as signiﬁcant (*P < 0.05, **P < 0.01,
***P < 0.001).
Results
Steady-state air–surface liquid dynamics
Airway Surface Liquid height (ASLh) measurements were
carried out over a period of 30 h to follow the dynamics
of epithelial ﬂuid absorption/secretion and to determine
the time course of the generation of a steady-state thin
ASL ﬁlm in CuFi-1 and NuLi-1 cell monolayers cultured
under an air–liquid interface. The rate of change in ASL
height and the ﬁnal steady-state ASLh were compared
between NuLi-1 and CuFi-1 monolayers following apical
addition of a thin ﬁlm of PBS solution to the epithelium
to establish an airway surface liquid layer (Fig. 1A). The
spontaneous change in ASL height reﬂects the combined
effects of absorption and secretion of electrolyte and
ﬂuid on ASL volume. We observed a faster instanta-
neous decline in ASLh to a lower steady-state level in
CF compared to the non-CF epithelia. At time zero of
PBS addition, the “starting” ASLh was higher in CuFi-1
compared to NuLi-1 epithelia, which most probably
reﬂects differences in the Texas red-dextran diffusion
within the mucus layers of different rheology between
Nuli-1 and CuFi-1, before transepithelial ion transport
ª 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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starts to modify the ASL height. However, what is
important for understanding the contribution of ion
transport to ASLh generation is the rate of ASLh decline
and the steady-state equilibrium values. Following addi-
tion of PBS, NuLi-1 monolayers exhibited a slower
decline in ASLh (1.19  0.02 lm/h), which reached a
steady-state value of 7.97  0.21 lm (n = 27) after 12 h
and 8.8  0.32 lm (n = 50) at 24 h. In contrast, CuFi-1
epithelia exhibited a faster rate of decline in ASLh
(2.24  0.02 lm/h) and a lower steady-state ASLh of
5.7  0.14 lm (n = 36 epithelia) after 12 h and
6.0  0.33 lm (n = 81) after 24 h. The difference
between the steady-state ASLh in NuLi-1 and CuFi-1
was statistically signiﬁcant across all time points mea-
sured (P < 0.001).
Lipoxin A4 increases ASL height in CF and
non-CF epithelia
LXA4 exposure resulted in a rapid increase in ASLh
within 15 min in both CuFi-1 and NuLi-1 epithelia. The
LXA4 concentration dependence of this response was
investigated in CuFi-1 cells over a range 1012 mol/L to
107 mol/L. The minimum LXA4 concentration that pro-
duced a signiﬁcant ASLh increase was 1011 mol/L and
the maximum effect was obtained at 108 mol/L
(Fig. 1B).
The time dependence of the effect of LXA4 on ASLh was
tested at 15-, 30-, 45-, and 60-min intervals following sta-
bilization of the ASLh. LXA4 was applied for “short-term”
periods of 15, 30, 45, and 60 min in NuLi-1 (Fig. 1C) and
CuFi-1 epithelia (Fig. 1D). LXA4 (1 nmol/L) treatment for
15 min increased ASLh by 51% in Nuli-1 epithelia
(n = 18) and doubled the ASLh in CuFi-1 epithelia
(n = 19). Longer LXA4 treatments did not produce any
further stimulation of ASLh, which showed a slow decrease
toward the steady state (Fig. 1C). Longer periods of LXA4
treatment for 24 h resulted in a sustained higher ASL in
CuFi-1 (Fig. 1D) but not in NuLi-1 monolayers (Fig. 1C),
and at 48 h the ASL height did not demonstrate a signiﬁ-
cant increase in either CuFi-1 or NuLi-1 monolayers.
Our experiments highlight that in control conditions,
the non-CF NuLi-1 cell monolayers are overlaid with a
continuous ASL layer, whereas the CF CuFi-1 monolayers
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Figure 1. LXA4 pretreatment increases ASL height in NuLi-1 and CuFi-1 monolayers. (A) ASL height was measured over a period of 30 h to
identify the time at which the ASL had stabilized. (B) LXA4 dose response (15 min treatment) on the ASL height increase in CuFi-1 epithelium.
(C) Typical confocal Z-sections of Nuli-1 and CuFi-1 (D) cell monolayers obtained by confocal microscopy in control conditions and after 15- and
60-min treatment by LXA4 (1 nmol/L). The ASL was stained with Dextran-Texas Red and cell monolayer (stained green with Calcein-AM). The
effect of LXA4 (1 nmol/L) on the ASL height depth in NuLi-1 nontreated epithelium and after 15, 30, 45, 60, min, 24 and 48-h treatments (E).
(F) The effect of LXA4 (1 nmol/L) on the ASL height measured 24 h after ASL labeling in CuFi-1 in nontreated epithelium and after 15, 30, 45,
60 min, 24, and 48-h treatments (***P < 0.001).
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have a disrupted and thinner ASL layer. The zones of
disrupted ASL could be explained by the presence of
secreted mucins and a localized dehydration of the ASL.
After LXA4 treatment of the CF cells, the ASL height
increased and the disruption of the ASL was eliminated
suggesting that LXA4 enhances ﬂuid secretion into the ASL
and inhibits mucin secretion by CF airway epithelial cells.
The ALX/FPR2 receptor mediates lipoxin A4
effects on ASL height
Evidence supporting a role for the ALX/FPR2 receptor in
mediating the effects of LXA4 came from studies using
Boc-2, a peptide antagonist ﬁrst reported to block inﬂam-
mation by binding to ALX/FPR2 (Gavins et al. 2003).
The receptor recognizes a variety of peptides, synthetic or
endogenously generated but with lower afﬁnity compared
to LXA4.
In NuLi-1 cells, Boc-2 pretreatment attenuated the
LXA4 induced ASLh increase from 14.26  0.67 lm
(n = 5) to 8.5  0.88 lm (n = 10, P < 0.001) (Fig. 2A).
Similarly, in CuFi-1 monolayers, Boc-2 pretreatment
inhibited the LXA4 stimulated ASLh increase from
12.04  0.42 lm (n = 8) to 5.29  0.27 lm (n = 3,
P < 0.001) (Fig. 2B).
LXA4 increases apical ALX/FPR2 membrane
abundance
The localization of the ALX/FPR2 receptor expression
was investigated using immunoﬂuorescence staining
on well-differentiated CuFi-1 epithelial monolayers
(Fig. 3A). Short-term stimulation of CuFi-1 monolayers
induced an apical increase in the integrated density of
the secondary Alexa-Fluor 488 signal for ALX/FPR2
(Fig. 3B). This apical translocation of the receptor was
accompanied by a concentration peak in the F-Actin sig-
nal at the membrane. The apical translocation of the
intensity of the ALX/FPR2 and F-actin signals indicate
cytoskeletal reformation in response to LXA4 exposure.
Expression of the ALX/FPR2 receptor was further inves-
tigated by FACS analysis. LXA4 treatment increased the
surface expression of the receptor in CuFi-1 cells (n = 4,
P < 0.05, t-test, Fig. 3C). Taken together, these results
indicate that the ALX/FPR2 receptor is localized in the
apical membrane of airway epithelial cells and that LXA4
stimulated trafﬁcking and abundance of the receptor at
the cell surface.
Contribution of amiloride-sensitive ion
transport to ASL height regulation by
lipoxin A4
The role of ENaC in the response of ASLh to LXA4 was
tested using the ENaC channel blocker amiloride. Apical
amiloride exposure induced a mean decrease of the trans-
epithelial short-circuit current (ISC) by 11.28  1.28 lA/
cm2 (from 14.40  2.40 to 3.10  0.56 lA/cm2 n = 9,
P < 0.05) in CuFi-1 monolayers compared to 1.96 
0.28 lA/cm2 (from 6.05  0.43 to 4.43  0.47 lA/cm2
n = 4, P < 0.05) in NuLi-1 monolayers (Fig. 4B). Thus,
ENaC activity accounts for a major component of the
total transepithelial current in CF cultures (approx. 78%)
and relatively little in non-CF cultures (33%). The
increased amplitude of the amiloride-sensitive ISC
response in CuFi-1 monolayers is consistent with a major
role for Na+ absorption through ENaC in generating the
transepithelial current following the loss of a contribution
by CFTR (Chen et al. 2010).
Acute LXA4 application to the apical or basolateral
chambers of the Ussing chambers did not result in any
change of the transepithelial current. In NuLi-1 cells,
LXA4 did not affect the amiloride-sensitive current
compared from a basal level of 1.96  0.28 lA/cm2 to
LXA4 treatment of 2.05  0.68 lA/cm2 (n = 8, Fig. 4A).
However, pretreatment with apical LXA4 reduced the
amiloride-sensitive current in CuFi-1 monolayers from
10.451.26 lA/cm2 to 6.39  0.58 lA/cm2 (n = 7,
P < 0.05, Fig. 4B).
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The signiﬁcance of inhibition of Na+ transport by
LXA4 was investigated on ASLh dynamics. In NuLi-1
cells, ENaC inhibition with amiloride did not affect the
ASLh (Fig. 4C). This result highlights that sodium
absorption does not contribute signiﬁcantly to the basal
ASLh in non-CF epithelia and is also consistent with the
low amiloride-sensitive currents observed under short-
circuit current conditions (Fig. 4A). In contrast, in CuFi-
1 cells, amiloride signiﬁcantly increased the ASLh from
5.3  0.2 lm (n = 7) to 9.6  0.3 lm (n = 6, P < 0.01,
Fig. 4D). These ﬁndings highlight the contribution of the
enhanced Na+ absorption to reduce the ASLh in the CF
epithelium. The contribution of Na+ absorption via
ENaC to the ASLh increase is shown in Figure 4D (gray
bars).
LXA4 independently stimulated a larger ASLh increase
than amiloride in CuFi-1 monolayers. Therefore, lipoxin
must affect two separate (amiloride-sensitive and amilo-
ride-insensitive) ion transporter systems to effect an
increase in ASLh. When added in combination, amiloride
and LXA4 produced additive effects on ASLh and the
contribution to the ASLh of the amiloride-insensitive
transporter can be deduced when compared to LXA4 and
amiloride alone and is highlighted in Figure 4D (black
bars). Assuming that the amiloride-sensitive and amilo-
ride-insensitive ion transporter effects are independent,
their respective contributions to the ASLh generation can
be calculated after LXA4 exposure. By this analysis, the
amiloride-sensitive and amiloride-insensitive currents
contributed 30% and 70%, respectively, to the LXA4-
mediated ASL height increase in the CF cultures
(Fig. 4D). Taken together, the results identify that ENaC
inhibition contributed 30% to the ASLh generation
induced by LXA4, while the remaining 70% was due to
the regulation of other ion channels, likely to be involved
in Cl secretion as shown below.
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Lipoxin A4 effects on bumetanide-sensitive
ion transport and ASL height
The two major conducting pathways involved in airway
transepithelial ion transport are Na+ absorption via ENaC
and Cl secretion via CFTR and Ca2+ -activated channels
(CaCC). Short-circuit current experiments with LXA4
pretreatment (1 nmol/L) of NuLi-1 monolayers for 15 min
increased the bumetanide-sensitive current from
2.90  0.21 lA/cm2 (n = 27) to 4.36  0.45 lA/cm2
(n = 6, P < 0.05, Fig. 5A). However, in CuFi-1 monolayers,
the basal bumetanide-sensitive current was almost absent
(0.49  1.9 lA/cm2, n = 9), whereas after 15 min pretreat-
ment with LXA4 (1 nmol/L) the transepithelial Cl
 current
increases to 3.73  0.98 lA/cm2 (n = 3, P < 0.05, Fig. 5B).
Exposure to basolateral bumetanide decreased the
steady-state ASLh in NuLi-1 epithelium from 7.3 
0.3 μm (n = 6) to 6.5  0.3 μm (n = 10, P < 0.001).
Similarly, the baseline ASLh in CuFi-1 monolayers was
signiﬁcantly decreased by bumetanide from 5.5  0.1 μm
(n = 29) to 4.8  0.1 μm (n = 24, P < 0.001). Bumeta-
nide abolished the ASLh increase induced by LXA4 in
NuLi-1 from 12.13  0.48 μm (n = 11) to a height of
6.29  0.29 μm (n = 8, P < 0.001, Fig. 5C). Similarly,
the LXA4-mediated ASLh increase in CuFi-1 was abol-
ished by bumetanide from a stimulated height of
11.12  0.27 μm (n = 30) to a height of 4.73  0.09 μm
(n = 23, P < 0.001, Fig. 5D) indicating a major contribu-
tion of Cl transepithelial transport to the stimulation of
ASLh by LXA4. We have already shown that LXA4 acti-
vates CaCC channels in CuFi-3 cells and CF primary
bronchial cell cultures (Bonnans et al. 2003; Verriere
et al. 2012). We could ﬁnd no effect of the CFTR inhibi-
tor Inh172 on Isc after LXA4 treatment (data not shown).
Thus, there is no evidence from speciﬁc CFTR inhibitor
studies that LXA4 stimulates deltaPhe508CFTR or its traf-
ﬁcking to the membrane.
Discussion
Cystic ﬁbrosis (CF) is a lethal genetic disorder resulting
from a mutation of the CFTR gene coding for a Cl
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channel normally localized in the apical membrane of epi-
thelial cells (Riordan et al. 1989). CF is characterized by
dehydration and reduction of the airway surface liquid
layer. This results in an impaired mucociliary clearance of
pathogens from the lung, chronic pulmonary infection,
and inﬂammation. Clearance of airway secretions has
been a ﬁrst-line therapy for CF patients (Pisi and Chetta
2009). CFTR functions as a cAMP-activated Cl channel
and as a regulator of other ion channels, such as inhibi-
tion of ENaC activity. In CF, the absence of CFTR repres-
sion of ENaC activity results in increased absorption of
Na+ and secondary dehydration of the ASL layer (Stutts
et al. 1995; Kunzelmann et al. 1997; Kunzelmann 2003).
ASL dehydration results in chronic bacterial infection,
persistent inﬂammation, and progressive lung destruction.
The majority of previous studies on ASL dynamics have
been performed using differentiated primary human epi-
thelial cells. Our approach using well-differentiated NuLi-
1 and CuFi-1 cell lines grown under thin ﬁlm conditions
has shown to be a robust and reproducible method of
measuring a dynamic ASL and thus provides a new model
system for CF ion transport and cell signaling and supple-
ment human primary tissue studies. ASL stabilization
kinetics demonstrated a more rapid attainment of plateau
values in the CF model when compared to the non-CF
monolayers. The mean plateau value of the stabilized
ASLh was reduced in the CF cell model which is consis-
tent with a diminished ASLh in CF airways (Boucher
2004a).
Short-term exposure to very low physiological (nanom-
olar) concentrations of LXA4 induced an increase in ASLh
in CF and non-CF bronchial epithelial cell lines. This
result is important for assessing a therapeutic role for
lipoxins in CF and is consistent with our previous publi-
cation showing that LXA4 at much higher concentrations
(100 nmol/L) also increased ASLh in airway epithelial
cells (Verriere et al. 2012). Here, we show a novel effect
for LXA4 in inhibiting ENaC activity in addition to its
pro-secretory action (Verriere et al. 2012) and resolution
of inﬂammation (Serhan and Savill 2005). Our results
contrast with a recent report indicating that LXA4 used at
100 nmol/L stimulated ENaC expression in A549 alveolar
cells, whereas LXA4 at lower concentrations of 1 and
10 nmol/L failed to affect ENaC (Wang et al. 2013).
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However, A549 cells may not be a good model to study
physiological responses to lipoxin in airway epithelia as it
has been previously reported that this alveolar cell line
does not express the ALX/FPR2 receptor (Bonnans et al.
2006), whereas the bronchial epithelial cells used in our
study show regulated expression of the speciﬁc receptor
for LXA4 (Buchanan et al. 2013).
The stimulatory effect of LXA4 on ASLh was main-
tained for over 24 h in CF epithelium. Although LXA4 is
rapidly metabolized (Serhan and Romano 1995; Clish
et al. 2000), LXA4 might induce long-lasting genomic
effects following the activation of its ALX/FPR2 receptor
such as expression of ion transporter and tight junction
proteins. The lasting positive effect on airway hydration
in CF may provide a novel route in correcting the deﬁ-
cient ASL dynamics in CF airway disease.
ASL depth is tightly regulated by the net transport of
Na+ absorption and Cl secretion (Matsui et al. 1998,
2000; Tarran and Boucher 2002). The lining of the airways
is characterized as mainly a Cl secretory epithelium. Acti-
vation of Cl channels in the apical membrane in the air-
way epithelium leads to efﬂux of Cl into the lumen. This
electrogenic Cl efﬂux provides the potential to drive Na+
and water across the epithelial tight junctions to provide
net transepithelial salt and water secretion into the lumen.
To maintain the chemical gradient and the membrane
potential, both under resting conditions and during Cl
secretion, Na+ and K+ exits across the basolateral mem-
brane via the Na+/K+ ATPase and basolateral potassium
channels, respectively (Jensen et al., 2001). The channels,
transporters, and pumps in all secretory epithelia operate
in concert to achieve net transepithelial ion transport.
Therefore, inhibition of any one of these pathways attenu-
ates the transepithelial transport of Cl, and consequently
decreases the rate of salt and water secretion (Jensen et al.,
2001). Our study demonstrates that lipoxin affects both
secretion and absorption in airway epithelium. In non-CF
bronchial epithelium, lipoxin increases ASL height by
inhibiting ENaC to decrease Na+ absorption and by acti-
vating CFTR to enhance Cl-secretion. In CF bronchial epi-
thelium, lipoxin restores ASL height mainly by inhibiting
ENaC in the absence of CFTR activity.
The ﬁndings strengthen evidence on the physiological
role of ENaC in maintaining the lung liquid balance as
demonstrated in mice in which the a-ENaC gene was inac-
tivated by homologous recombination (Hummler et al.,
1996). Neonatal mice developed respiratory distress and
died prematurely at 40 h from failure to clear the lungs of
ﬂuid. Patients with pseudohypoaldosteronism who exhibit
functional loss of ENaC have an excess ASL due to reduced
Na+ absorption (Kerem et al., 1999). In this group of
patients, the accelerated mucus transport is probably due
to increased ASL as demonstrated by Tarran et al. (2001).
In CF, changes in Na+ absorption are secondary to
absence of the CFTR channel (Chen et al. 2010) due to
release of inhibition from CFTR (Stutts et al. 1995; Kun-
zelmann et al. 1997). Acute addition of LXA4 did not
affect the Isc. We also tested the effects at 15, 30, 45, and
60 min and there was no effect on Isc at all time frames.
This result is not surprising given the opposite effects of
LXA4 to inhibit Na
+ absorption (decreases Isc) and stim-
ulate Cl secretion (increases Isc) which may cancel out
any net change in Isc. The data from short-circuit current
and ASLh measurements (under open-circuit conditions)
are internally consistent. In the non-CF cultures, LXA4
has little effect on both amiloride-sensitive ISC and ASLh.
In contrast, in the CF cultures, the amiloride-sensitive ISC
accounts for ~80% of the total ISC and this is reﬂected in
the large effects of amiloride on ASLh.
We demonstrated that LXA4 stimulates a bumetanide-
sensitive Cl current coupled to ASLh regulation in both
normal and CF airway epithelia. This result is consistent
with our previous report showing that LXA4 stimulated a
calcium-dependant Cl transport (Bonnans et al. 2003;
Verriere et al. 2012). Thus, LXA4 increases the ASL height
in CF epithelium by two complementary pathways
through inhibiting Na+ hyperabsorption via ENaC and
stimulating Cl secretion via CaCC channels. The dual
effect of LXA4 on ENaC and CaCC strengthens the rele-
vance of our ﬁndings for a possible therapeutic effect of
LXA4 to reverse all of the ion transport dysfunction in CF
airway epithelium to restore a physiological ASL height.
LXA4 binds to the ALX/FPR2 receptor to elicit its
effects in a variety of cells (Serhan et al. 1984; Serhan
1997). Here, we report for the ﬁrst time the presence of
ALX/FPR2 expression in CF airway epithelial cells.
Although the ALX/FPR2 receptor protein is expressed in
the cytoplasm, it appears to be predominately expressed
at the apical membrane of airway epithelial monolayers.
A role for LXA4 on cytoskeleton reorganization has been
shown in monocytes and macrophages (Maderna et al.
2002) and is consistent with our ﬁndings that the ALX/
FPR2 receptor is translocated to the apical surface upon
exposure to LXA4.
Donabedian and Gallin (1981) showed that there was a
transient agonist-induced decrease in the number of FPR-
binding sites in response to an agonist, and that these
binding sites could return to the cell surface if the cells
were kept at 37°C (Donabedian and Gallin 1981). The
study demonstrated a recycling pool of formyl peptide
receptors. Jesaitis and colleagues initiated studies of for-
myl peptide receptor interaction with the cytoskeleton,
and found that a receptor–cytoskeleton complex was
formed before receptor internalization which was resistant
to Triton X-100 (Jesaitis et al. 1984, 1985). The ﬁndings
revealed that FPRs interact with intracellular cytoskeletal
ª 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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proteins which affected the binding properties of the
receptor. Further studies on recombinant FPR1 demon-
strated agonist-induced actin polymerization and chemo-
taxis in transfected HL-60 cells (Prossnitz et al. 1993).
LXA4 induces signals that regulate BLT1, production of
chemokines, cytokines (e.g., TNF) growth factor receptors
(e.g., VEGF) in human leukocytes, and mucosal epithelial
cells, each contributing to regulate the resolution of the
inﬂammatory cycle (Serhan and Savill 2005). The level of
control by LXA4 of key processes relevant to acute
inﬂammation raises the question of how LXA4 binding to
FPR2/ALX may translate into anti-inﬂammatory and pro-
resolving properties. FPR2/ALX is phosphorylated in an
agonist-dependent manner, but little is known about the
kinases involved and the determinants responsible for its
internalization have not yet been recognized. Phosphory-
lation of these receptors is known to affect their internali-
zation; it would be interesting to determine if constitutive
phosphorylation of FPR2/ALX is related to its cell surface
expression pattern.
The increase in ASLh induced by LXA4 through the
inhibition of Na+ hyperabsorption and stimulation of Cl
secretion may prove to be of therapeutic value in CF by
correcting normal ion transport, restoring ASLh and hydra-
tion, and improving mucociliary clearance. The effect of
LXA4 in CF cultures raises interesting implications for its
potential use in a clinical setting. Currently, drug therapy
for CF is limited to the G551D mutation with the potentia-
tor VX-770 which is restricted to a small percentage (4%)
of CF patients. The beneﬁcial effects of LXA4 on ASL
dynamics may not have such a restricted genotypic use as it
corrects the general NaCl transport dysfunction and may
complement existing therapies to enhance airway mucocili-
ary clearance and prevent ASL depletion.
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